Advertisement

Advertisement

MIRA Stock Latest News

Mira reports positive results in 7-day dog study for obesity candidate SKNY-1

The FlyMira reports positive results in 7-day dog study for obesity candidate SKNY-1

MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1

PremiumCompany Announcements

MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1

7d ago

MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice

PremiumCompany Announcements

MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice

13d ago

Mira Pharmaceuticals provides update on MIRA-55, SKNY-1

PremiumThe Fly

Mira Pharmaceuticals provides update on MIRA-55, SKNY-1

14d ago

MIRA Pharmaceuticals announces positive preclinical results for MIRA-55

PremiumCompany Announcements

MIRA Pharmaceuticals announces positive preclinical results for MIRA-55

1M ago

Mira Pharmaceuticals reports formulation results for MIRA-55

PremiumThe FlyMira Pharmaceuticals reports formulation results for MIRA-55

1M ago

MIRA Reports Positive Preclinical Data for SKNY-1 Program

Company Announcements

MIRA Reports Positive Preclinical Data for SKNY-1 Program

1M ago

Mira Pharmaceuticals reports SKNY-1 formulation results

The Fly

Mira Pharmaceuticals reports SKNY-1 formulation results

1M ago

MIRA Unveils Differentiated Preclinical Data for Mira-55

PremiumCompany Announcements

MIRA Unveils Differentiated Preclinical Data for Mira-55

2M ago

Mira Pharmaceuticals reports preclinical pharmacology data on Mira-55

PremiumThe Fly

Mira Pharmaceuticals reports preclinical pharmacology data on Mira-55

2M ago

Psychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial

PremiumThe Fly

Psychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial

2M ago

MIRA Advances Ketamir-2 Into FDA-Accepted Phase 2a Trial

PremiumCompany Announcements

MIRA Advances Ketamir-2 Into FDA-Accepted Phase 2a Trial

2M ago

Mira Pharmaceuticals submits Phase 2a trial protocol to U.S. FDA for Ketamir-2

PremiumThe FlyMira Pharmaceuticals submits Phase 2a trial protocol to U.S. FDA for Ketamir-2

2M ago

Psychedelic: Optimi Health completes psilocybin export to the UK

The Fly

Psychedelic: Optimi Health completes psilocybin export to the UK

2M ago

MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer

Company Announcements

MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer

2M ago

Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003

PremiumThe Fly

Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003

2M ago

MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline

PremiumCompany Announcements

MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline

2M ago

Mira Pharmaceuticals secures worldwide rights to MIRA-55, SKNY-1

PremiumThe Fly

Mira Pharmaceuticals secures worldwide rights to MIRA-55, SKNY-1

2M ago

Psychedelic: Optimi Health advances natural psilocybin extract

PremiumThe Fly

Psychedelic: Optimi Health advances natural psilocybin extract

3M ago

Mira Pharmaceuticals secures worldwide rights for Ketamir-2

PremiumThe FlyMira Pharmaceuticals secures worldwide rights for Ketamir-2

3M ago

MIRA Expands Global Ketamir-2 License for Clinical Development

Company Announcements

MIRA Expands Global Ketamir-2 License for Clinical Development

3M ago

Mira Pharmaceuticals management to meet with Maxim

The Fly

Mira Pharmaceuticals management to meet with Maxim

3M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >